High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer

Hook microtubule-tethering protein 3 (HOOK3) is an adaptor protein for microtubule-dependent intracellular vesicle and protein trafficking. In order to assess the role of HOOK3 in prostate cancer we analyzed HOOK3 expression by immunohistochemistry on a TMA containing more than 12,400 prostate cancers. Results were compared to tumor phenotype and PSA recurrence as well as aberrations possibly defining relevant molecular subtypes such as ERG status and deletions of 3p13, 5q21, 6q15 and PTEN. HOOK3 immunostaining was negative in normal luminal cells of prostate epithelium, whereas 53.3% of 10,572 interpretable cancers showed HOOK3 expression, which was considered low in 36.4% and high in 16.9% of cases. High-level HOOK3 expression was linked to advanced tumor stage, high Gleason score, high proliferation index, positive lymph node stage, and PSA recurrence (p<0.0001 each). The prognostic role of HOOK3 expression was independent of established clinico-pathological parameters both in preoperative and postoperative settings. Comparisons with molecular features were performed to draw conclusions on the potential function of HOOK3 in the prostate. A strong association with all examined deletions is consistent with a role of HOOK3 for maintaining genomic integrity by contributing to proper centrosome assembly. Finding HOOK3 expression in 74% of ERG positive but in only 38% of ERG negative cancers (p<0.0001) further suggests functional interactions between these genes. In conclusion, the results of our study identify HOOK3 as a strong candidate prognostic marker with a possible role in maintaining genomic integrity in prostate cancer, which may have potential for inclusion into clinical routine assays.

[1]  S. Kurtz,et al.  Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.

[2]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[3]  E. Wieben,et al.  The genomic landscape of small intestine neuroendocrine tumors. , 2013, The Journal of clinical investigation.

[4]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[5]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[6]  S. Dedhar,et al.  Integrin-Linked Kinase Regulates Interphase and Mitotic Microtubule Dynamics , 2013, PloS one.

[7]  Yuzhuo Wang,et al.  Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. , 2012, Carcinogenesis.

[8]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[9]  Bruce J Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[10]  Tim Beißbarth,et al.  TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.

[11]  A. Le Bivic,et al.  Hook2 is involved in the morphogenesis of the primary cilium , 2011, Molecular biology of the cell.

[12]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[13]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[14]  Hartwig Huland,et al.  Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.

[15]  K. Friedrich,et al.  Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer. , 2010, Analytical and quantitative cytology and histology.

[16]  L. Tsai,et al.  Hook3 Interacts with PCM1 to Regulate Pericentriolar Material Assembly and the Timing of Neurogenesis , 2010, Neuron.

[17]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[18]  C. Cooper,et al.  ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.

[19]  S. Gygi,et al.  An FTS/Hook/p107(FHIP) complex interacts with and promotes endosomal clustering by the homotypic vacuolar protein sorting complex. , 2008, Molecular biology of the cell.

[20]  K. Nielsen,et al.  Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.

[21]  E. Lundberg,et al.  A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies* , 2008, Molecular & Cellular Proteomics.

[22]  J. Köllermann,et al.  Identifizierung und Validierung klinisch relevanter molekularer Veränderungen im Prostatakarzinom , 2008, Der Urologe.

[23]  L. Foster,et al.  Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization , 2008, The Journal of cell biology.

[24]  T. Giordano,et al.  HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. , 2007, Endocrine-related cancer.

[25]  H. Krämer,et al.  Hook2 Localizes to the Centrosome, Binds Directly to Centriolin/CEP110 and Contributes to Centrosomal Function , 2007, Traffic.

[26]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[27]  Viviane Poupon,et al.  Mammalian late vacuole protein sorting orthologues participate in early endosomal fusion and interact with the cytoskeleton. , 2003, Molecular biology of the cell.

[28]  Xinran Liu,et al.  The Golgi-Associated Hook3 Protein Is a Member of a Novel Family of Microtubule-Binding Proteins , 2001, The Journal of cell biology.

[29]  H. Krämer,et al.  Genetic analysis of hook, a gene required for endocytic trafficking in drosophila. , 1999, Genetics.

[30]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[31]  Rafael J. Yáñez-Muñoz,et al.  Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. , 2011, American journal of cancer research.

[32]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[33]  J. Köllermann,et al.  [Identification and validation of clinically relevant molecular alterations in prostate cancer]. , 2008, Der Urologe. Ausg. A.

[34]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.